311 Therapeutic Potential of Opioids in Narcolepsy Type 1 Table 2: Characteristics of the study population NT1 with recent opioid use (N=16) NT1 without recent opioid use (N=84) P-value Male:female (N:N) 6:10 36:48 0.691 Age at study inclusion (in years, mean, SD) 50.6 (17.0) 36.5 (14.7) 0.001 Cataplexy (presence/total available) 16/16 81/84 0.443 Cataplexy frequency (N, %) Never: 0 (0.0) <1/year: 0 (0.0) 1/year-1/month: 0 (0.0) 1/month-1/week: 1 (6.3) 1/week-1/day: 6 (37.5) >1/day: 7 (43.8) N=14 Never: 3 (3.6) <1/year: 0 (0.0) 1/year-1/month: 2 (2.4) 1/month-1/week: 7 (8.3) 1/week-1/day: 20 (23.8) >1/day: 38 (45.2) N=70 0.921 Epworth sleepiness scale score (mean, SD) 14.4 (3.1) N=8 15.4 (4.1) N=60 0.495 Hypocretin level (N, %) <40: 2 (50.0) 40-110: 1 (25.0) 110-200: 1 (25.0) >200: 0 (0.0) N=4 <40: 21 (63.6) 40-110: 9 (27.3) 110-200: 3 (9.1) >200: 0 (0.0) N=33 0.587 HLA DQB1*0602 (presence/total available) 9/9 65/66 0.710 MSLT sleep latency (minutes, mean, SD) 3.3 (1.4) N=14 4.0 (2.4) N=64 0.296 MSLT SOREMP (mean, SD) 2.8 (1.1) N=15 2.9 (1.3) N=68 0.883 PSG SOREMP (presence/total available) 4/13 43/79 0.114 EDS = excessive daytime sleepiness; HLA = human leukocyte antigen; MSLT = multiple sleep latency test; NT1 = narcolepsy type 1; PSG = polysomnography; SOREMP = sleep-onset rapid eye movement period. 10
RkJQdWJsaXNoZXIy MjY0ODMw